Maintenance therapy with pemetrexed and erlotinib resulted in improved progression-free survival compared with second-line therapy at disease progression. In the second-line setting, pemetrexed ...

Brain metastases are a common problem in patients with EGFR -mutated non-small cell lung cancer (NSCLC), occurring in about ...

For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing. We’ve issued final ...

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The reversible TKIs erlotinib and gefitinib, which selectively target EGFR, were shown to improve disease outcomes in non-small-cell lung cancer (NSCLC) patients with EGFR mutations, and this ...

Additionally, the trial combining gemcitabine with erlotinib resulted in an improved HR for survival of 0.82 (P = 0.038) and remains the only large, phase III trial to show an overall survival ...

Twenty years on, the amended product patent regime has had its moments. And intellectual property experts say it’s time to ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

For example, as cancers grow, they form new blood vessels that nourish them. It is used with the standard chemotherapy regimen. Medications with other specific targets, such as crizotinib, erlotinib ...

Results: Of the 32, 520, 983 reports in VigiBase, 23, 181, 539 were eligible for the analysis. Significant cardiovascular signals were identified for 17 TKIs, including erlotinib, gefitinib, and ...